Zobrazeno 1 - 10
of 1 190
pro vyhledávání: '"11"'
Autor:
Christine A. Iacobuzio-Donahue, Francesco Maura, Ahmet Dogan, Heather Landau, Amit Verma, Rachel Zeig-Owens, Shani Irby, Kylee H Maclachlan, Orsolya Giricz, Sohrab P. Shah, David J. Prezant, Benjamin Diamond, Even H Rustad, Jessica Hong, Andriy Derkach, Venkata Yellapantula, Mayris P. Webber, Elli Papaemmanuil, Ola Landgren, David G. Goldfarb, Michael Crane, Urvi A Shah, Laura Crowley, Malin Hultcrantz, Yanming Zhang
Publikováno v:
Clin Cancer Res
Purpose: The World Trade Center (WTC) attack of September 11, 2001 created an unprecedented environmental exposure to known and suspected carcinogens. High incidence of multiple myeloma and precursor conditions has been reported among first responder
Autor:
Clara D. Bloomfield, Bayard L. Powell, Andrew J. Carroll, Shelley Orwick, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Bhavana Bhatnagar, Dimitrios Papaioannou, Richard Stone, Deedra Nicolet, Krzysztof Mrózek, John C. Byrd, Jonathan E. Kolitz, Christopher J. Walker, James S. Blachly
Publikováno v:
Leukemia. 34:358-368
Sole trisomies of chromosomes 4, 8, 11, 13 and 21 account for 89–95% of all sole trisomies in adult AML patients. We analyzed clinical and molecular characteristics of 138 de novo AML patients with sole +4, +8, +11, +13 or +21, and compared them wi
Autor:
Lisa A. Carey, Patrick L. Leslie, Yvonne L. Chao, Alessandro Porrello, Yi-Hsuan Tsai, Emily B. Harrison, Joel S. Parker, Subrata K. Ghosh, Brian C. Cooley, Chad V. Pecot, Amanda E.D. Van Swearingen
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Nature Communications
Nature Communications
Lymph node (LN) metastases correspond with a worse prognosis in nearly all cancers, yet the occurrence of cancer spreading from LNs remains controversial. Additionally, the mechanisms explaining how cancers survive and exit LNs are largely unknown. H
Autor:
Jacob J. Orme, C. Richard Choo, Val J. Lowe, Matthew J. Iott, Michael S. Bold, Brian A. Costello, Mark A. Nathan, Henan Zhang, Haidong Dong, Thomas M. Pisansky, Erik J. Tryggestad, J. Fernando Quevedo, Eugene D. Kwon, Debra H. Brinkmann, William S. Harmsen, Kenneth R. Olivier, Lance C. Pagliaro, Brian J. Davis, Sean S. Park, F. Abraha, Fabrice Lucien, Geoffrey B. Johnson, B.J. Stish
Publikováno v:
Clin Cancer Res
Purpose: Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers are lacking. Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e603c86f7a18480ea887972a21dc48b
https://europepmc.org/articles/PMC8639778/
https://europepmc.org/articles/PMC8639778/
Autor:
Robert O. Greer, Jeffrey Eskendri, Marileila Varella-Garcia, Aline Murakami-Walter, Moni Ahmadian, Paul D. Freedman
Publikováno v:
Journal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 47(2)
Background Glandular odontogenic cyst (GOC) demonstrates a significant predilection toward localized biologic aggressiveness and recurrence. GOC shares certain histopathologic features with intraosseous mucoepidermoid carcinoma (IMEC). The current in
Autor:
Guohua Zhang, James Z. Zhu, Min Li, Yan Zuo, Jeffrey A. Frost, Zicheng Zhang, Yi-Ping Li, Thomas K. Sin
Publikováno v:
Cancer Res
Cancer-associated cachexia, characterized by muscle wasting, is a lethal metabolic syndrome without defined etiology or established treatment. We previously found that p300 mediates cancer-induced muscle wasting by activating C/EBPβ, which then upre
Autor:
Kouji Matsushima, Mizuho Hasegawa, Eri Nakamura, Kazutoshi Shibuya, Takashi Nishina, Daisuke Ohshima, Wakami Takeda, Norihiro Tada, Chiharu Nishiyama, Tetuo Mikami, Mizuho Nakayama, Shigeyuki Shichino, Hiroyasu Nakano, Mika Kawauchi, Masato Ohtsuka, Hideo Yagita, Naohiro Inohara, Satomi Adachi-Akahane, Masanobu Oshima, Soh Yamazaki, Yuko Kojima, Yutaka Deguchi, Satoshi Ueha
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-20 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-20 (2021)
Interleukin (IL)-11 is a member of the IL-6 family of cytokines and is involved in multiple cellular responses, including tumor development. However, the origin and functions of IL-11-producing (IL-11+) cells are not fully understood. To characterize
Autor:
Arati V. Rao, Thomas Oellerich, S. Haihua Chu, Alison Walker, Anjali Cremer, Federica Piccioni, Amy Goodale, Gabriela Alexe, James S. Blachly, Björn Häupl, Linda Ross, Elizabeth S. Frank, Amanda L. Robichaud, John C. Byrd, Scott A. Armstrong, Yana Pikman, Jana M. Ellegast, Kimberly Stegmaier, Sebastian Mohr
Publikováno v:
Cancer Discov
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of res
Autor:
Michele Connelly, Jia Xie, Nathaniel R. Twarog, Natasha Sahr, Jessica Gartrell, Hyekyung P. Cho, Anang A. Shelat, Sara M. Federico, Kaley Blankenship, Marcia Mellado-Largarde, Jiyang Yu, Christopher L. Tinkle, Geoffrey Neale, Elizabeth Stewart, Lauren Hoffmann, Koon-Kiu Yan, Armita Bahrami, Shondra M. Pruett-Miller, April Sykes, Michael R. Clay, Shaina N. Porter
Publikováno v:
Mol Cancer Ther
Pediatric sarcomas represent a heterogeneous group of malignancies that exhibit variable response to DNA-damaging chemotherapy. Schlafen family member 11 protein (SLFN11) increases sensitivity to replicative stress and has been implicated as a potent
Autor:
Benjamin G. Neel, Mitchell J. Geer, Kwok-Kin Wong, Brian Diskin, Takamitsu Hattori, Paolo Mita, Kai Wen Teng, Connor Foster, Joshua Leinwand, Carmine Fedele, Akiko Koide, Ting Chen, Wei Wang, Shohei Koide, Shuai Li, Kwan Ho Tang, Yubao Wang, David H. Peng, Jiehui Deng, Hao Ran, Igor Dolgalev, George Miller, Ugur Ozerdem
Publikováno v:
The Journal of Experimental Medicine
G12C inhibitors (G12C-Is) have significant but limited efficacy in KRAS-mutant malignancies, mostly due to “adaptive resistance.” Combining SHP2 inhibitor (SHP2-I) with G12C-I abrogates adaptive resistance; evokes beneficial, tumor-specific chang